Furthermore, the combination therapy with ESKM and TKIs showed superior efficacy than monotherapy with only TCRm ESKM or TKIs.331 Many small-molecule agents, such as proteasome inhibitors, histone deacetylase inhibitors, and MEK inhibitors, are capable of upregulating MHC expression and presentation, which facilitate pMHC-targeted tumor therapy.332 For example, our previous study showed that the MEK inhibitor trametinib augmented the antitumor efficacy of EA1 HL-vcMMAE both in vitro and in vivo by increasing MART-126–35 peptide presentation.328. The gene discussed is MAP2K7; the disease is neoplasm.